Quviviq

Chemical Namedaridorexant
Dosage FormTablets (oral; 25 mg, 50 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyIdorsia Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Quviviq (daridorexant) Prescribing Information.2022Idorsia Pharmaceuticals US Inc., Radnor, PA